Karen Moorhouse, ITIA President, on Swiatek: "An unusual case of contamination of a regulated product in Poland".

The tennis world is in uproar. World No. 2 Iga Swiatek tested positive for trimetazidine and accepted a one-month suspension.

The decision has already caused a stir, even though the news broke only a few hours ago.
Karen Moorhouse, President of the ITIA (International Tennis Integrity Agency), reacted to the situation.

"After establishing the source of trimetazidine, it became clear that this was an extremely unusual case of contamination of a regulated product in Poland," she said.

"But this product does not have the same name worldwide, and the fact that it is a regulated drug in one country may not be enough to avoid any level of responsibility.

This case is an important reminder to tennis players of the strict liability for violations of the World Anti-Doping Code and the importance of players being more careful when using supplements and medications.

Due diligence is imperative to minimize the risk of unintentional anti-doping rule violations such as this," concludes Moorhouse.